|1.||Kester, Mark: 9 articles (10/2015 - 05/2005)|
|2.||Cabot, Myles C: 8 articles (10/2015 - 08/2010)|
|3.||Spinedi, Angelo: 4 articles (03/2015 - 12/2002)|
|4.||Shanmugavelandy, Sriram S: 4 articles (09/2013 - 10/2011)|
|5.||Fox, Todd E: 4 articles (06/2013 - 07/2010)|
|6.||Loughran, Thomas P: 3 articles (10/2015 - 01/2013)|
|7.||Di Bartolomeo, Sabrina: 3 articles (03/2015 - 12/2002)|
|8.||Liu, Xin: 3 articles (06/2013 - 08/2010)|
|9.||Chapman, Jacqueline V: 3 articles (07/2011 - 08/2010)|
|10.||Gouazé-Andersson, Valérie: 3 articles (07/2011 - 08/2010)|
07/01/2010 - "Our results provide new insights into the effects of C(6)-ceramide on HERG channels and suggest that C(6)-ceramide can be a promising therapeutic for cancers that overexpress HERG."
03/01/2012 - "N-Hexanoylsphingosine (C6-Cer) is currently being evaluated as an antineoplastic agent, after preclinical studies showing its property to reduce tumor growth. "
01/01/2015 - "Nanoliposomal formulation of C6-ceramide, a proapoptotic sphingolipid metabolite, presents an effective way to treat malignant tumor. "
01/01/2013 - "Finally, an in vivo murine model of CLL shows that nanoliposomal C6-ceramide treatment elicits tumor regression, concomitant with GAPDH downregulation. "
01/01/2013 - "When C6-ceramide is encapsulated in a nanoliposome bilayer formulation, cell death is selectively induced in tumor models. "
01/01/2013 - "We conclude that selective inhibition of the glycolytic pathway in CLL cells with nanoliposomal C6-ceramide could potentially be an effective therapy for leukemia by targeting the Warburg effect. "
08/01/2010 - "KG-1 leukemia cells favored C6-SM synthesis at low (0.6muM) and high-dose (12muM) C6-ceramide. "
11/01/2008 - "While C6-ceramide can activate PP2A in acute leukemia cells, the sphingolipid did not activate the phosphatase in K562 cells. "
11/01/2013 - "Using an in-vivo P388/ADR leukemia mouse model, the median survival time of the DOX-loaded PEGylated micelles with PazPC and C6-ceramide as major components was significantly greater than that of free DOX and control group. "
06/01/2013 - "Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia."
|3.||Breast Neoplasms (Breast Cancer)
06/01/2012 - "In this study, we determined whether the introduction of an AC inhibitor would enhance the apoptosis-inducing effects of C6-ceramide (C6-cer) in breast cancer cells. "
08/01/2010 - "MDA-MB-231 breast cancer cells decreased the amount of C6-ceramide metabolized to C6-sphingomyelin (C6-SM) and increased the amount metabolized to C6-glucosylceramide (C6-GC) in response to increasing concentrations. "
01/01/2015 - "Here, we provide evidence that acute treatment (30 min) of melanoma and breast cancer cells with nanoliposomal C6-ceramide (NaL-C6) may suppress cell migration without inducing cell death. "
06/01/2012 - "C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth."
05/02/2003 - "We found that for C(6)-, C(8)-, C(10)-, C(14)- and C(16)-ceramide, the chain length was inversely proportional to cytotoxic activity, with C(6)-ceramide being most active (IC(50) values in the 3-14 microM range) and C(16)-ceramide being least active (IC(50) values in excess of 100 microM) in the MDA435/LCC6 human breast cancer and J774 mouse macrophage cell lines investigated. "
05/01/2005 - "Here, we report that the systemic i.v. delivery of C6-ceramide (C6) in a pegylated liposomal formulation significantly limited the growth of solid tumors in a syngeneic BALB/c mouse tumor model of breast adenocarcinoma. "
12/01/2013 - "In this study, we have used label-free Raman micro-spectral analysis and kinetic modeling to study cellular interactions and intracellular delivery of C6-ceramide using a non-targeted and an epidermal growth factor receptor (EGFR) targeted biodegradable polymeric nano-delivery systems, in EGFR-expressing human ovarian adenocarcinoma (SKOV3) cells. "
07/01/2008 - "In this study, we have investigated the biodistribution and pharmacokinetic analysis of paclitaxel (PTX) and the apoptotic signaling molecule, C6-ceramide (CER), when administered in a multifunctional polymer-blend nanoparticle formulation to female nude mice bearing an orthotopic drug sensitive MCF7 and multidrug resistant MCF7 TR (MDR-1 positive) human breast adenocarcinoma. "
|5.||Myeloid Leukemia (Leukemia, Myelocytic)
|7.||Estrogen Receptor Modulators (Antiestrogen)
|8.||Epidermal Growth Factor Receptor (EGF Receptor)
|1.||Photochemotherapy (Photodynamic Therapy)
|2.||Heterologous Transplantation (Xenotransplantation)